CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)

Inclusion criteria

• for Procurement and T-cell Production:
• Age ≤21 years old
• Relapsed/refractory CD123+ disease defined as follows: AML/MDS
• Relapsed disease: Patients developing recurrent disease after a first complete remission (CR)
• Refractory disease: Patients not achieving a CR after 2 cycles of induction chemotherapy B-cell ALL
• Relapsed disease that is CD123 positive and CD19 negative/dim or patients otherwise ineligible for CD19 directed therapies including
• Patients in 2nd or greater relapse
• Patients with relapse after allogeneic HSCT
• Refractory disease that is CD123 positive and CD19 negative/dim or patients otherwise ineligible for CD19 directed therapies T-cell All • Relapsed refractory disease that is CD123 positive BPDCN • Relapsed/refractory disease that has failed front-line therapy
• Estimated life expectancy of \>12 weeks
• Karnofsky or Lansky (age-dependent) performance score ≥50
• Patients with a history of prior allogeneic HCT must be clinically recovered from prior HCT therapy, have no evidence of active GVHD and have not received a donor lymphocyte infusion (DLI) within the 28 days prior to apheresis
• Patient must have an identified, suitable HCT donor
• For females of child-bearing age:
• Not lactating with intent to breastfeed
• Not pregnant with negative serum pregnancy test within 7 days prior to enrollment
• Meets eligibility criteria to undergo autologous apheresis, or have previously undergone autologous apheresis

Exclusion criteria

• Known primary immunodeficiency
• History of HIV infection
• Severe intercurrent uncontrolled bacterial, viral or fungal infection (e.g. active hepatitis B or C infection or adenovirus infection)
• History of hypersensitivity reactions to murine protein-containing products
• Patients with acute promyelocytic leukemia (APL, t (15;17))
• Known contraindication to the protocol defined lymphodepleting chemotherapy regimen of fludarabine/cyclophosphamide. Inclusion Criteria for Treatment:
• Age≤21 years old
• Detectable disease that is CD123+ (at least MRD+ disease)
• Estimated life expectancy of \>8 weeks
• Karnofsky or Lansky (age-dependent) performance score≥50
• Patients with a history of prior allogeneic HCT must be clinically recovered from prior HCT therapy, have no evidence of active GVHD and have not received a donor lymphocyte infusion (DLI) within the 28 days prior to planned infusion
• Patient must have an identified, suitable HCT donor
• Adequate cardiac function defined as left ventricular ejection fraction \>40%, OR shortening fraction ≥25%
• EKG without evidence of clinically significant arrhythmia
• Adequate renal function defined as creatinine clearance or radioisotope GFR ≥50 ml/min/1.73m2 (GFR ≥40 ml/min/1.73m2 if \< 2 years of age)
• Adequate pulmonary function defined as forced vital capacity (FVC)≥50% of predicted value; or pulse oximetry≥92% on room air if patient is unable to perform pulmonary function testing
• Total Bilirubin≤3 times the upper limit of normal for age, except in subjects with Gilbert's syndrome
• Alanine aminotransferase (ALT) OR aspartate aminotransferase (AST) ≤5 times the upper limit of normal for age
• Has recovered from all NCI CTAE grade III-IV, non-hematologic acute toxicities from prior therapy
• For females of child-bearing age
• Not lactating with intent to breastfeed
• Not pregnant with negative serum pregnancy test within 7 days prior to enrollment
• If sexually active, agreement to use birth control until 3 months after T- cell infusion. Male partners should use a condom.
• Available autologous transduced T-cell product that has met GMP release criteria Exclusion Criteria:
• Known primary immunodeficiency
• History of HIV infection
• Severe intercurrent uncontrolled bacterial, viral or fungal infection
• History of hypersensitivity reactions to murine protein-containing products
• History of severe hypersensitivity reactions to cornstarch or hydroxyethyl starch.
• Receiving systemic steroids therapy exceeding the equivalent of 0.5 mg/kg/day of methylprednisolone, in the 7 days prior to CD123-CAR T- cell infusion
• Receiving systemic therapy in the 14 days prior to CD123-CAR T-cell infusion, which will interfere with the activity of the CD123-CAR T cells in vivo (in the opinion of the study PI(s))
• Receiving rituximab therapy in the 30 days prior to CD123-CAR T cell infusion. (This exclusion criterion is intended to prevent premature exposure of CD123-CAR T cells to rituximab, which would activate the safety switch and promote CAR T-cell apoptosis).
• Receiving intrathecal chemotherapy in the 7 days prior to CD123-CAR T cell infusion.
• Known contraindication to the protocol defined lymphodepleting chemotherapy regimen of fludarabine/cyclophosphamide.
• Active CNS disease